University of California, Los Angeles, researchers investigate gene therapy as an HIV treatment, Gizmodo reports.

The Associated Press writes that gene therapy has now shown that it could be harnessed to treat disease.

One Mayo Clinic doctor isn't sure of the value of genome sequencing, NPR reports.

Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.

As more people have their genomes sequenced, some researchers seek to enable mechanisms for genome data donation, similar to organ and tissue donation.

With a two-stage atrial fibrillation GWAS, researchers took a crack at untangling the pathways, regulatory features, and tissue types contributing to the heart condition.

A University of Alabama at Birmingham-led team has found that mutations within five NF1 codons are linked to an increased likelihood of severe neurofibromatosis symptoms.

23andMe is embarking on a large-scale study of weight loss, according to Technology Review.

A continuing resolution keeps the US government funded, but gives uncertainty to science agencies's budgets, ScienceInsider says.

Colorado Representative Ed Perlmutter writes at Scientific American that the new US tax bill will impede scientific research.

The newly launched LunaDNA hopes that its community model of compensating individuals for contributing genomic and health information will lead to better research.

The company expects to see lower growth in products and services due to timing issues in obtaining billable cases from contracted customers.

The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.

A new fruit fly genome sequence has uncovered additional variation that affects key fly traits.

The New York Times looks into the protein work David Baker is doing at the University of Washington.

Wired writes that researchers are searching for ways to improve upon CRISPR gene editing.

In Genome Biology this week: tumor-associated macrophage patterns in glioma, systems epigenomics algorithm, and more.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.

The firm said the charges, related to deferred tax assets, revaluation of deferred tax liabilities, and other tax provisions, won't affect its adjusted EPS.

The two companies have signed a new master collaboration agreement under which HTG will  develop custom assays for use in earlier stages of Merck's drug development process.

OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.

Marcus Schabacker, a board-certified anesthesiologist and intensivist, has been named CEO and president of ECRI Institute, a health services research organization with an interest in genetic testing. Schabacker, who has 18 years of leadership experience in the medical device and pharmaceutical industries, recently served as chief scientific officer of Baxter. He previously helped Nelson Mandela rebuild South Africa's rural health system in the post-Apartheid era. Schabaker will replace Jeffrey Lerner, who is retiring Dec. 31 after 16 years as ECRI president and CEO.